Eisai Expands Marketing and Supply Agreement for Anti-obesity Agent Lorcaserin to Include Most Countries Worldwide

Hatfield, England (ots/PRNewswire) -

Eisai announces today that it has expanded the marketing and
supply agreement between its U.S. subsidiary Eisai Inc. and U.S-based
Arena Pharmaceuticals Inc.'s Swiss subsidiary, Arena Pharmaceuticals
GmbH, for the anti-obesity agent lorcaserin hydrochloride
(lorcaserin) (U.S. brand name: BELVIQ(R)). Whilst the existing
agreement granted Eisai Inc. exclusive rights to market and
distribute lorcaserin in 21 countries throughout the Americas, the
expanded agreement now includes most countries and territories
worldwide, most notably, the member states of the European Union,
Japan and China (but excludes South Korea, Taiwan, Australia, New
Zealand and Israel).

Under this agreement, Eisai will be working in collaboration with
Arena to develop and seek marketing authorisation of lorcaserin as an
anti-obesity treatment in its territories. In addition to pursuing
regulatory approval for weight management in the expanded
territories, Eisai and Arena plan to investigate the potential of
lorcaserin in new areas, such as: smoking cessation, a once-daily
formulation, a fixed-dose combination with phentermine, as well as
explore lorcaserin's impact on diabetes and cardiovascular outcomes.

Lorcaserin is marketed in the U.S. by Eisai Inc., and is approved
by the U.S. Food and Drug Administration (FDA) as an adjunct to a
reduced-calorie diet and increased physical activity for chronic
weight management in adult patients with an initial body mass index
(BMI) of 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence
of at least one weight-related co-morbid condition. Marketing
authorization has also been applied for in Mexico and Canada.

In recent years, obesity has become a major global health problem,
with more than 1.4 billion adults worldwide believed to be overweight
and approximately 500 million of that number qualifying as obese.[1]
By region, around 170 million people in the United States[2] and 150
million people in Europe are reported to be obese or overweight.[3]
In Europe, it is estimated that 10-30% of adults are obese.[4]

Eisai is dedicated to discovering, developing and producing
innovative therapies that can make a difference and impact the lives
of patients and their families. This passion for people is part of
Eisai's human health care (hhc) mission, which strives for better
understanding of the needs of patients and their families to increase
the benefits health care provides.

Notes to Editors

About BELVIQ(R) (lorcaserin hydrochloride)

Discovered and developed by Arena Pharmaceuticals, Inc.,
lorcaserin is a new chemical entity that is believed to decrease food
consumption and promote satiety in individuals by selectively
activating serotonin 2C receptors in the brain. Lorcaserin was
launched in the United States in June 2013 after receiving a final
scheduling designation from the U.S. Drug Enforcement Administration
(DEA).

About Eisai

Eisai is one of the world's leading research and development (R&D)
based pharmaceutical companies, and we define our corporate mission
as "giving first thought to patients and their families and to
increasing the benefits health care provides," which we call human
health care (hhc).

Eisai concentrates its R&D activities in three key areas:

- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc.
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home
market of Japan, Eisai employs more than 10,000 people worldwide.
From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently
expanded its business operations to include Europe, the Middle East,
Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing
operations in over 20 markets, including the United Kingdom, France,
Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria,
Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the
Netherlands, Belgium, Luxembourg, Russia and the Middle East.

For further information please visit our web site
http://www.eisai.co.uk

About ArenaPharmaceuticals

Arena is a biopharmaceutical company focused on discovering,
developing and commercialising novel drugs that target G
protein-coupled receptors, or GPCRs, to address unmet medical needs.
Arena's US operations are located in San Diego, California, and its
operations outside of the United States, including its commercial
manufacturing facility, are located in Zofingen, Switzerland.

For more information, visit Arena's website at
http://www.arenapharm.com

Arena Pharmaceuticals(R) and Arena(R) are registered service marks
of Arena Pharmaceuticals, Inc. BELVIQ(R) is a registered trademark of
Arena Pharmaceuticals GmbH.

1. World Health Organisation. Data and statistics for Obesity.
World Health Organisation. Data and statistics for Europe.
http://www.who.int/mediacentre/factsheets/fs311/en
[http://www.who.int/mediacentre/factsheets/fs311/en ]. Last accessed
7 November 2013

2. American Heart Association. http://www.heart.org/idc/groups/hea
rt-public/@wcm/@sop/@smd/documents/downloadable/ucm_319588.pdf . Last
accessed 7 November 2013.

3. World Health Organisation. Data and statistics for Europe
http://www.euro.who.int/__data/assets/pdf_file/0008/98243/E89858.pdf.
Last accessed 7 November 2013

4. World Health Organisation. Data and statistics for Europe. http
://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity
/data-and-statistics . Last accessed 7 November 2013.

Date of preparation: November 2013

Job code: Corporate-UK2020

ots Originaltext: Eisai Europe Limited
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media Enquiries: Eisai Europe Ltd, Cressida Robson / Charlotte
Andrews, +44(0)7908 314 155 / +44(0)7947 231 513,
Cressida_Robson@eisai.net, Charlotte_Andrews@eisai.net. Tonic Life
Communications, Siobhan Reilly / April Kenneally, +44(0)207 798 9999
/
+44(0)207 798 9263, siobhan.reilly@toniclc.com,
april.kenneally@toniclc.com.